Soluble CD163 performance as non-invasive biomarker of different liver conditions

CAIROLI V,; CASCIATO P; GIADANS C; AMEIGEIRAS B; DE MATTEO E; PRECIADO MV; VALVA P

Congreso; XXVI ALEH Congreso on line; 2021

ALEH

INTRODUCTION: Development of noninvasive tests to predict liver injury represents a current goal. Soluble CD163 (sCD163) is a specific plasma biomarker of macrophage activation with promising clinical relevance in estimating damage severity and predicting the outcome in different liver conditions.AIM: To evaluate sCD163 performance as a non-invasive marker of liver damage.MATERIALS AND METHODS: sCD163 was quantified by enzyme-linked-immunosorbent assay in plasma from 123 patients (57 HCV, 20 HCV/HIV, 10 HBV, 36 MAFLD) obtained at time of liver biopsy. 20 healthy donors were included as controls. sCD163 values were compared among disease conditions and related to histological parameters of liver damage. Diagnostic performance was assessed by the area under the receiver operating characteristic curves (AUROC). RESULTS: Patients´ sCD163 levels [0.579g/L (0.034 -3.596)] were higher than controls´ [0.221g/L (0.116-0.549)] (p